Boston Scientific Corporation (NYSE:BSX) Short Interest Update

Boston Scientific Corporation (NYSE:BSX) was the target of a significant growth in short interest in the month of August. As of August 31st, there was short interest totaling 48,173,758 shares, a growth of 74.4% from the August 15th total of 27,617,554 shares. Based on an average daily volume of 21,036,931 shares, the short-interest ratio is currently 2.3 days. Currently, 3.3% of the shares of the company are sold short.

Boston Scientific Trading Down 0.8%

NYSE BSX traded down $0.35 on Thursday, hitting $43.56. The company’s stock had a trading volume of 32,559,134 shares, compared to its average volume of 20,532,774. The company’s 50-day moving average is $46.93 and its 200 day moving average is $53.64. The firm has a market cap of $63.13 billion, a PE ratio of 17.64, a PEG ratio of 1.02 and a beta of 0.57. Boston Scientific has a 1-year low of $42.20 and a 1-year high of $105.65. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. The company had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. Boston Scientific’s revenue was up 7.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, analysts predict that Boston Scientific will post 3.29 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. Weiss Ratings lowered shares of Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Tuesday, July 7th. Piper Sandler restated an “overweight” rating and set a $65.00 target price on shares of Boston Scientific in a research report on Friday, June 12th. Jefferies Financial Group dropped their price target on Boston Scientific from $100.00 to $67.00 and set a “buy” rating for the company in a research note on Wednesday, June 24th. Royal Bank Of Canada lowered their price objective on shares of Boston Scientific from $85.00 to $70.00 and set an “outperform” rating for the company in a research report on Thursday, July 30th. Finally, Needham & Company LLC dropped their target price on shares of Boston Scientific from $77.00 to $57.00 and set a “buy” rating for the company in a report on Wednesday, July 8th. Twenty-three research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $71.04.

Insider Buying and Selling

In related news, CEO Michael F. Mahoney purchased 186,240 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The shares were acquired at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the purchase, the chief executive officer owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This represents a 13.27% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Edward J. Ludwig bought 5,000 shares of the firm’s stock in a transaction dated Friday, July 31st. The stock was purchased at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the transaction, the director directly owned 30,359 shares of the company’s stock, valued at $1,380,727.32. The trade was a 19.72% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have acquired 194,522 shares of company stock valued at $9,385,210. 0.34% of the stock is owned by insiders.

Institutional Investors Weigh In On Boston Scientific

Several institutional investors and hedge funds have recently made changes to their positions in BSX. BlackRock Inc. bought a new stake in Boston Scientific in the second quarter valued at approximately $5,534,781,000. State Street Corp raised its holdings in Boston Scientific by 1.4% during the 4th quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock worth $6,278,422,000 after purchasing an additional 920,495 shares during the last quarter. Primecap Management Co. CA bought a new position in Boston Scientific during the 2nd quarter worth approximately $2,156,233,000. Capital World Investors lifted its position in shares of Boston Scientific by 1.9% in the 4th quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock worth $2,588,953,000 after purchasing an additional 502,627 shares during the period. Finally, Norges Bank bought a new stake in shares of Boston Scientific in the 4th quarter valued at $2,199,395,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation is a medical device company that develops, manufactures and markets products used in minimally invasive procedures. Its technologies are designed to diagnose and treat a range of medical conditions while supporting less invasive alternatives to traditional surgery.

The company’s products address cardiovascular, endoscopy, urology, pelvic health and neuromodulation applications. Its portfolio includes devices used in cardiac rhythm management and electrophysiology, structural heart procedures, peripheral and vascular interventions, gastrointestinal procedures, kidney stone and prostate treatments, and therapies for chronic pain and other neurological conditions.

Founded in 1979, Boston Scientific serves healthcare providers and patients in markets around the world.